Immunoglobulin therapy

Johnston, Sarah; Hollingsworth, Rob

doi:10.7861/clinmedicine.16-6-576

Cited by 7 publications

(3 citation statements)

References 8 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, of these 11 patients, 8 had ITP, in which cases the number of doses is usually relatively low (Cines and Bussel 2005). Moreover, the immunomodulatory dose of IVIG was 743 mg/kg, lower than the typical dose of 1-2 g/kg (Johnston and Hollingsworth 2016), and represented only a small portion of all infusions (13.2%). Treatmentrelated AEs were not particularly associated with immunomodulatory doses (Fig.…”

Section: Discussionmentioning

confidence: 98%

Surveillance study on the tolerability and safety of Flebogamma^®DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients

Alsina

Mohr²,

Montañés

et al. 2017

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Direct comparisons of tolerability and safety of concentrated intravenous immunoglobulin (IVIG) versus less concentrated products are scarce. In this postauthorization, prospective, observational, multicenter study, a systematic comparison of 10% and 5% concentrations of Flebogamma® DIF IVIG was performed in both adult and pediatric patients treated with the studied IVIG products according to the approved indications under routine conditions. Dose of product administered, adverse events (AEs), physical assessments, laboratory tests, and concomitant therapy were analyzed. Patient recruitment in the 10% and 5% product groups was, respectively, 34 (32 analyzed, 13 of them children, receiving 130 IVIG infusions) and 35 (34 analyzed, receiving 135 IVIG infusions). Twenty‐four infusions (18.5%; 95% CI: 11.8, 25.1) with the 10% product and 3 (2.2%; 95% CI: −0.3, 4.7) with the 5% product were associated with potentially treatment‐related AEs (P < 0.0001). Nine patients (28.1%) infused with the 10% product and 3 (8.8%) infused with the 5% product presented, respectively, 33 and 8 treatment‐related AEs (of which 7 and 6, respectively, were serious AEs, experienced by only three hypersensitive patients). The profile of AEs occurring with the infusion of 10% and 5% products were comparable. The most frequent treatment‐related AEs were headache (n = 17, 3 patients; 15 episodes, 1 patient) and pyrexia (n = 6, 4 patients). In conclusion, no unpredictable risk was detected for both Flebogamma DIF 10% and 5% concentrations, which were therefore deemed as safe and well‐tolerated IVIG in the studied population. The frequency of infusions associated with treatment‐related AEs was lower with the 5% concentration.

show abstract

Section: Discussionmentioning

confidence: 98%

Surveillance study on the tolerability and safety of Flebogamma^®DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients

Alsina

Mohr²,

Montañés

et al. 2017

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…In comparison to our previous investigations using the same animal model without any therapeutic intervention (Ücal et al, 2017), the control groups of the current study receiving a isotype matched control antibody (C1 and C2) showed less demyelination (PLP loss: 1.0 ± 0.2 (d15) vs 0.4 ± 0.2 (C1) and 0.3 ± 0.1 (C2), d15 animal without therapy and isotype antibody treated), suggesting a more favorable impact on the observed cellular patterns, although the demyelination was invariably distinctive compared to the anti-CD20 treated groups. This effect is, presumably, attributable to a similar phenomenon already known from the studies that have reported a bene cial impact of unspeci c immunoglobulin therapy (e.g., Johnston and Hollingsworth, 2016). As a clinical standard therapy, unspeci c antibodies obtained from blood preservations are used to treat several immune-mediated diseases to enable formation of unspeci c complexes, which thereby inactivate pathogenic antibodies.…”

Section: Discussionmentioning

confidence: 61%

Anti-CD20 Treatment Effectively Attenuates Cortical Pathology in a Rat Model of Widespread Cortical Demyelination

Haindl

Üçal

Klaus

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundCortical demyelination represents a prominent feature of the multiple sclerosis (MS) brain, especially in (late) progressive stages. We recently developed a new rat model that reassembles critical features of cortical pathology characteristic to progressive types of MS. In persons affected by MS, B-cell depleting anti-CD20 therapy proved successful in the relapsing remitting as well as the early progressive course of MS, with respect to reducing the relapse rate and number of newly formed lesions. However, if the development of cortical pathology can be prevented or at least slowed down is still not clear. The main goal of this study was thus to increase our understanding for the mode of action (MOD) of B-cells and B-cell directed therapy on cortical lesions in our rat model. MethodsFor this purpose, we set up two separate experiments, with two different induction modes of B-cell depletion. Brain tissues were analyzed thoroughly using histology. ResultsWe observed a marked reduction of cortical demyelination, microglial activation, astrocytic reaction and apoptotic cell loss in anti-CD20 antibody treated groups. At the same time, we noted increased neuronal preservation compared to control groups, indicating a favorable impact of anti-CD20 therapy. ConclusionThese findings might pave the way for further research on the MOD of B-cells and therefore help to improve therapeutic options for progressive MS.

show abstract

“…Natural Abs (Nabs) are major components of intravenous immunoglobulin (IVIg) therapy, delivered as pools from serum of healthy donors. It is used mainly as replacement therapy for patients with primary/secondary immune deficiency disorders or as immunomodulatory therapy in a wide range of autoimmune and inflammatory conditions, with a variable evidence base [ 104 ]. In liver transplant recipients, IVIg therapy was associated with a significant reduction of fungal infections [ 105 ], while it was not the case in hematopoietic stem cell transplant recipients [ 106 ].…”

Section: Introductionmentioning

confidence: 99%

Humoral Immunity Against Aspergillus fumigatus

Dellière

Aimanianda

2023

Mycopathologia

View full text Add to dashboard Cite

Aspergillus fumigatus is one the most ubiquitous airborne opportunistic human fungal pathogens. Understanding its interaction with host immune system, composed of cellular and humoral arm, is essential to explain the pathobiology of aspergillosis disease spectrum. While cellular immunity has been well studied, humoral immunity has been poorly acknowledge, although it plays a crucial role in bridging the fungus and immune cells. In this review, we have summarized available data on major players of humoral immunity against A. fumigatus and discussed how they may help to identify at-risk individuals, be used as diagnostic tools or promote alternative therapeutic strategies. Remaining challenges are highlighted and leads are given to guide future research to better grasp the complexity of humoral immune interaction with A. fumigatus.

show abstract

Immunoglobulin therapy

Cited by 7 publications

References 8 publications

Surveillance study on the tolerability and safety of Flebogamma^®DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients

Surveillance study on the tolerability and safety of Flebogamma^®DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients

Anti-CD20 Treatment Effectively Attenuates Cortical Pathology in a Rat Model of Widespread Cortical Demyelination

Humoral Immunity Against Aspergillus fumigatus

Contact Info

Product

Resources

About

Immunoglobulin therapy

Cited by 7 publications

References 8 publications

Surveillance study on the tolerability and safety of Flebogamma®DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients

Surveillance study on the tolerability and safety of Flebogamma®DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients

Anti-CD20 Treatment Effectively Attenuates Cortical Pathology in a Rat Model of Widespread Cortical Demyelination

Humoral Immunity Against Aspergillus fumigatus

Contact Info

Product

Resources

About

Surveillance study on the tolerability and safety of Flebogamma^®DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients

Surveillance study on the tolerability and safety of Flebogamma^®DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients